KY19334

KY19334 is a CXXC5-DVL inhibitor. KY19334 can activate the Wnt/β-catenin pathway by inhibiting CXXC5-Dvl interaction. KY19334 can inhibit cancer cells proliferation, migration, invasion and transformation by inhibiting CDK1. KY19334 can accelerate wound healing and exert regenerative effects. KY19334 can be used for the researches of cancer, inflammation, metabolic and neurological disease, such as cutaneous squamous cell carcinoma and diabetes[1].

Product Specifications

CAS Number

[2319609-67-9]

UNSPSC

12352005

Target

CDK; Wnt; β-catenin

Related Pathways

Cell Cycle/DNA Damage; Stem Cell/Wnt

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Cancer; Metabolic Disease; Inflammation/Immunology; Neurological Disease

Smiles

O=C(NC1=C/2C=C(OC)C=C1)C2=C3NC4=CC=CC=C4C/3=N\O

Molecular Formula

C17H13N3O3

Molecular Weight

307.30

References & Citations

[1]Lee SH, et al. Novel small molecules downregulate CDK1 expression and inhibit Wnt/β-catenin signaling in cutaneous squamous cell carcinoma by targeting its distinct tumor-specific cellular landscape. Exp Mol Med. 2025 Sep;57 (9) :1996-2009.|[2]Kim E, et al. Inhibiting the cytosolic function of CXXC5 accelerates diabetic wound healing by enhancing angiogenesis and skin repair. Exp Mol Med. 2023 Aug;55 (8) :1770-1782.